POST-COVID-19 EOSINOPHILIC PNEUMONIA
Chest
; 162(4):A602, 2022.
Article
in English
| EMBASE | ID: covidwho-2060644
ceftazidime; dexamethasone; endogenous compound; furosemide; interleukin 13; interleukin 4; interleukin 5; levofloxacin; oxygen; prednisone; remdesivir; tocilizumab; vancomycin; adverse drug reaction; aged; bacteremia; bodily secretions; bronchiectasis; bronchoscopy; bronchus; bronchus secretion; case report; clinical article; complication; conference abstract; coronavirus disease 2019; deterioration; differential diagnosis; drug combination; drug therapy; dyspnea; emphysema; eosinophil; eosinophilia; fibrosis; fungus; ground glass opacity; high flow nasal cannula therapy; hospitalization; human; human cell; inflammation; intravenous drug administration; Loeffler pneumonia; lung biopsy; lung lavage; male; methicillin resistant Staphylococcus aureus; methicillin resistant Staphylococcus aureus infection; nasal cannula; nonhuman; organizing pneumonia; oxygenation; pleura effusion; pneumonia; psoriasis; respiratory distress; rheumatoid arthritis; side effect; smoking; superinfection; Th2 cell; thorax; X ray film
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Long Covid
/
Variants
Language:
English
Journal:
Chest
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS